Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model

BACKGROUND: A multiple-target tyrosine kinase inhibitor, nintedanib, which is approved for treatment of interstitial pulmonary disease, has been demonstrated to have anti-fibrotic activity outside of the lungs. We explored its therapeutic effect in a murine model of peritoneal fibrosis. METHODS: Dai...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Binbin, Yu, Chao, Zhang, Shenglei, Hou, Xiying, Wang, Yi, Wang, Jun, Zhuang, Shougang, Liu, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386418/
https://www.ncbi.nlm.nih.gov/pubmed/36157259
http://dx.doi.org/10.1159/000523852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386418/
https://www.ncbi.nlm.nih.gov/pubmed/36157259
http://dx.doi.org/10.1159/000523852

Ejemplares similares